Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Opdivo Qvantig

(op-DEE-voh kyoo-VAN-tig)
A combination of two drugs used alone or with other drugs to treat adults with certain types of colorectal cancer, esophageal cancer, gastric (stomach) cancer, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma (a type of liver cancer), melanoma, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), squamous cell carcinoma of the head and neck, and urothelial carcinoma (a type of cancer in the bladder or urinary tract). Nivolumab binds to a protein called PD-1, which is found on some normal cells and some types of cancer cells. Nivolumab may block PD-1 and help the immune system kill cancer cells. Hyaluronidase allows nivolumab to be given by injection under the skin. Opdivo Qvantig can be given in less time than nivolumab alone, which is given as an infusion. Also called nivolumab and hyaluronidase.
More Information
Search NCI's Dictionary of Cancer Terms